Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP003 for Chronic Fatigue and Post-COVID Fatigue
NCT06739720Phase 3Recruiting
- Sponsor
- The University of Hong Kong
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS) and post-COVID condition (PCC) (2 arms), sponsored by The University of Hong Kong. Primary endpoint: Chalder Fatigue Score at 6 weeks. Started Jan 2025; status: recruiting.
02
Conditions
myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS)post-COVID condition (PCC)
Beyond the preview
Go deeper on NCT06739720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06739720.